Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.

Chereshnev VA, Bocharov G, Bazhan S, Bachmetyev B, Gainova I, Likhoshvai V, Argilaguet JM, Martinez JP, Rump JA, Mothe B, Brander C, Meyerhans A.

Int Rev Immunol. 2013 Jun;32(3):282-306. doi: 10.3109/08830185.2013.779375. Epub 2013 Apr 25. Review.

PMID:
23617796
2.

Genetic CD21 deficiency is associated with hypogammaglobulinemia.

Thiel J, Kimmig L, Salzer U, Grudzien M, Lebrecht D, Hagena T, Draeger R, Voelxen N, Bergbreiter A, Jennings S, Gutenberger S, Aichem A, Illges H, Hannan JP, Kienzler AK, Rizzi M, Eibel H, Peter HH, Warnatz K, Grimbacher B, Rump JA, Schlesier M.

J Allergy Clin Immunol. 2012 Mar;129(3):801-810.e6. doi: 10.1016/j.jaci.2011.09.027. Epub 2011 Oct 27. Erratum in: J Allergy Clin Immunol. 2014 Feb;133(2):604. Völxen, Nadine [corrected to Voelxen, Nadine].

PMID:
22035880
3.

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.

Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.

AIDS Res Hum Retroviruses. 2012 May;28(5):437-46. doi: 10.1089/AID.2011.0050. Epub 2011 Oct 17.

PMID:
21902621
4.

[Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment].

Rump JA, Schönborn H.

Z Rheumatol. 2010 Dec;69(10):903-9. doi: 10.1007/s00393-010-0652-y. German.

PMID:
20532789
5.

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.

AIDS. 2010 Jan 2;24(1):55-65. doi: 10.1097/QAD.0b013e32833032ed.

PMID:
19926964
6.

Myelodysplastic syndrome with complex karyotype associated with long-term highly active antiretroviral therapy.

Rieg S, Lübbert M, Kern WV, Timme S, Gärtner F, Rump JA.

Br J Haematol. 2009 Jun;145(5):670-3. doi: 10.1111/j.1365-2141.2009.07665.x. Epub 2009 Mar 17. No abstract available.

PMID:
19344389
7.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

8.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

9.

Hepatotoxicity in patients prescribed efavirenz or nevirapine.

Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzold D, Hartmann M.

Eur J Med Res. 2008 Jul 28;13(7):343-8.

PMID:
18700192
10.

Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).

Hartmann M, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzoldt D.

Int J STD AIDS. 2005 Jun;16(6):404-9.

PMID:
15969773
11.

Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.

Möbius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt E, Christensen S, Rump JA, Fätkenheuer G, Behrens GM, Schmidt RE.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):174-80.

PMID:
15905733
12.

[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].

Hartmann M, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzoldt D.

Hautarzt. 2005 Sep;56(9):847-53. German.

PMID:
15726299
13.

Prognostic value of proliferative responses to HIV-1 antigen in chronically HIV-infected patients under antiretroviral therapy.

Mohm JM, Rump JA, Schulte-Mönting J, Schneider J.

J Clin Virol. 2004 Jul;30(3):239-42.

PMID:
15135742
14.

Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.

Grotz WH, Breitenfeldt MK, Braune SW, Allmann KH, Krause TM, Rump JA, Schollmeyer PJ.

Transpl Int. 2001;14(1):16-23.

15.

Granulocyte colony-stimulating factor (G-CSF) may stimulate HIV-replication during cytostatic chemotherapy.

Weiner SM, Rump JA, Kreise W, Thimme R, Blum HE, Meyerhans A, Schneider J.

Eur J Haematol. 1998 Nov;61(5):354-5. No abstract available.

PMID:
9855252
16.

Treatment of bone pain after kidney transplantation.

Grotz W, Rump JA, Niessen A, Schmidt-Gayk H, Schollmeyer P.

Transplant Proc. 1998 Aug;30(5):2114-6. No abstract available.

PMID:
9723410
18.

Isolation of Helicobacter pullorum from patients with enteritis.

Steinbrueckner B, Haerter G, Pelz K, Weiner S, Rump JA, Deissler W, Bereswill S, Kist M.

Scand J Infect Dis. 1997;29(3):315-8.

PMID:
9255900
19.

Clinical utility of cytomegalovirus urine cultures for ophthalmic care in patients with HIV.

Gellrich MM, Baumert E, Rump JA, Vaith P, Hufert FT, Hansen LL.

Br J Ophthalmol. 1996 Sep;80(9):818-22.

20.

[Indications for eye examination of HIV patients--screening parameters for cytomegalovirus retinitis].

Gellrich MM, Lagrèze WD, Rump JA, Hansen LL.

Klin Monbl Augenheilkd. 1996 Aug-Sep;209(2-3):72-8. German.

PMID:
8992086

Supplemental Content

Loading ...
Support Center